HIMS
Hims & Hers Health, Inc.
stock NYSE

Voo, GLD,HIMS,DZP, NBIS, BMNR, MSFT

I bought the HIMS dip im ready for it to go flaccid again next week (please go up).

If NVDA takes HIMS and stays above $190 then ber will be in the stratosphere on Bezo’s Penis Rocket 9000

Buy shares set trailing stop.
I’m up 5% on some stuff from open with high beta like HIMS, SOFI, ACHR

I would love to buy myself some more NVO, NU, MAIN and HIMS (not really a value stock), but I don't have any cash left at the moment.
Salary arrives in 2 weeks so will get some then if the prices are still down.

You are probably not wrong. Just not right enough. If we're talking pure alpha in the metabolic disease game, let's zoom east to Hong Kong where the real fireworks are popping off. I'm eyeing Innogen-B (02591.HK) and PegBio (02565.HK) as straight-up superior moonshots right now, all laser-focused on the GLP-1 revolution that's exploding in Asia's massive diabetes and obesity market. These aren't diluted plays like UNH's insurance sprawl or HOOD's trading volatility; they're razor-sharp biotechs riding China's 1.4 billion-person wave, with approvals incoming and valuations that make US counterparts look like overpriced lattes. Let me break down why swapping some of that bag for these HK gems could 5x your portfolio by 2028—pure fire, no fluff.
First off, the macro setup in Hong Kong biotech is straight dominance mode. While the US Nasdaq biotech index is grinding up a measly 20% this year, Hong Kong's Hang Seng Biotech Index has ripped 80%+, outrunning even AI hype. Why? Beijing's pumping state cash into "Made in China 2025" for pharma independence, with 14 fresh listings already raising over HK$18 billion in 2025—quadrupling last year's haul—and 36 more queued up. Valuations? HK biotechs trade at 8-10x forward sales on average, versus 18x+ for US peers, giving you dirt-cheap entry into 30%+ CAGR growth as Asia's diabetes epidemic (hello, 140 million cases and counting) meets ultra-long-acting GLP-1s that crush Ozempic's dosing hassle. No DOJ probes or Medicare cuts here—just streamlined NMPA nods and export pipelines to Southeast Asia. HIMS is cute with its telehealth subs, but it's a US middleman facing Amazon's boot; these HK plays own the IP and manufacturing in the world's fastest-scaling market.
Take Innogen-B: This beast just exploded 296% on debut in August, opening at HK$72 after pricing at HK$18.68, and it's still humming around HK$50-60 with HK$683 million fresh in the tank from an IPO oversubscribed 5,365 times—HK$370 billion in bids from 260k investors, second-hottest in Hong Kong this year. Their crown jewel, Efsubaglutide Alfa (branded Diabegone), is Asia's first homegrown humanized long-acting GLP-1 agonist, already greenlit for type 2 diabetes in China and barreling through late-stage trials for obesity and MASH (that fatty liver goldmine worth $30 billion globally). Early data? 7% weight drop in four weeks, with monthly dosing that laps weekly shots—perfect for compliance in a market where 80% of patients ghost treatments. They're deploying IPO cash for Phase III global pushes, commercial ramps, and CNS add-ons, turning red ink (losses narrowed to HK$175 million last year) into black by mid-2026. Compared to HIMS' 50x P/E bloat and GLP-1 supply glut risks, Innogen's at <5x sales with zero revenue yet—pure asymmetry. Bears whine about Eli Lilly/Novo competition, but Innogen's local pricing edge (half the cost) and China-first moat mean they snag 10-15% market share easy, printing HK$10 billion revenue by 2030. UNH? It's a sleepy dividend cow at 13x earnings, dodging cyber headaches but capped at 8-10% growth; Innogen's your uncapped rocket to HK$300/share.
Then PegBio seals the deal as the stealth assassin. Listed earlier this year at HK$15.60, raising HK$301 million for a HK$6 billion val, it dipped to HK$10 on open but clawed back to HK$15+ on pipeline heat—up 7% monthly despite broader volatility. Their lead, PB-119, is another long-acting GLP-1 banger for diabetes and obesity, with NMPA acceptance last year and marketing greenlight eyed for Q1 2026. Preclinicals on PB-2301 (GLP-1/GIP dual) and PB-2309 (triple agonist) target NASH and rare endocrines, diversifying beyond HIMS' one-trick pony. R&D burn was HK$280 million in 2022, tapering to HK$76 million YTD as trials wrap, with cash at HK$27 million pre-IPO now beefed for launch and expansions. Losses ticked up slightly to HK$283 million last year on zero revenue, but that's biotech math—post-approval, ARPU from chronic scripts hits HK$500/year per patient in a 500 million obese Asian pool. Versus HOOD's cyclical 70% transaction reliance (hello, 35% revenue crater in '22), PegBio's recurring revenue moat is ironclad, with PEGylation tech for custom peptides adding service upside. Analysts are mum on ratings yet, but the sector tailwind screams Buy; at 4x projected sales, it's a steal next to UNH's regulatory quicksand (DOJ antitrust, 85% loss ratios). PegBio could 4x to HK$60 by 2027 if PB-119 captures 5% China share, while HOOD prays for bull markets.
Bottom line, apes: HIMS/HOOD/UNH are fine for balanced bags, but Innogen and PegBio are the asymmetric edges—cheaper entries, explosive China growth (20% GDP healthcare slice by 2030), and GLP-1 purity without US baggage. HK's policy rocket fuel means 50-100% pops on approvals alone, while US names grind through comps and comps. I'm allocating 20% here; dips under HK$45 for Innogen and HK$12 for PegBio are no-brainers. DYOR, markets flip fast, but this is where the smart money's flowing east. Who's jumping in? 🚀🇭🇰 #HKBiotech #GLP1Bets

I've recently started using Moomoo's AI for stock analysis and stock picking. I asked it to identify 10 potential 5-bagger stocks, and here’s the list it generated:
NVDA, AMD, SYM, SERV, NIO, UPST, HIMS, XPEV, VRTX, MRVL
Curious to hear—have any of you used Moomoo AI for investing? What’s been your experience?

Yo apes, dropping my two cents on the long-term bull/bear showdown for HIMS, HOOD, and UNH because someone asked for the real tea, not the CNBC fluff. This is 3-5 year horizon stuff, not day-trade noise, so buckle up. Everything here is fresh off Nov 2025 data—earnings, filings, analyst takes, short interest, the works. No copypasta, all reworded in my own voice. Let’s ride.
Starting with HIMS, the telehealth rocket that’s up triple digits this year and chilling around forty-five bucks a share. Forward earnings multiple is chunky at 50x, but the growth is stupid: 80%+ revenue pops projected straight through 2027, mostly riding the GLP-1 weight-loss wave plus mental health and women’s health add-ons. They’ve got 1.5 million subscribers now, average revenue per user climbing 20% year-over-year, and EBITDA margins just cracked 15%. Cash flow per share could hit five bucks by 2028 if they keep compounding. Hedge funds are stacking in—38 big players now versus 31 last quarter. Zacks slapped a Strong Buy on it. Bull case says they grab 5% of a hundred-billion-dollar telehealth pie and the stock prints two hundred or higher by decade’s end. The Novo Nordisk breakup? Shorts calling it a disaster, but bulls say it’s a nothing-burger—HIMS just pivots to their own compounded versions and keeps the party going.
Flip the script to the bear side and things get spicy. Short interest still north of 15%, gross margins are juicy at 80% but operating costs are ballooning. GLP-1 supply is gonna flood the market by 2027 and crush pricing power; right now 40% of revenue is one category. Amazon Pharmacy and Teladoc are lurking with deeper pockets and real infrastructure. DCF on the dark side spits out twenty bucks a share if growth throttles to 20%. One guy on here already dumped his entire bag calling the moat “non-existent.” DOJ is sniffing around compounding rules, and recessions make people skip the $99/month subscription real quick. Net-net, I’m tilting bullish if you buy dips under forty, but if the weight-loss hype dies, bears feast.
Next up, HOOD—the meme broker that turned legit and sits at $130 after a 150% YTD rip. Funded accounts over 25 million and growing 30% year-over-year, average revenue per user north of $150 thanks to crypto trading (20% of revenue), margin loans, and Robinhood Gold subs hitting a million users. They’re sitting on six billion cash, zero debt, and just bought a crypto wallet to keep expanding. Crypto ETFs are soaking up fifty billion in inflows, retail is back in force, and 24/7 trading plus new ETF launches scream “everything app” for millennials and Gen Z. Technicals show a consolidation triangle ready to break; Mizuho’s old fourteen-dollar target got obliterated months ago. Bull case says three hundred to four hundred by 2030 if the risk-on party keeps rolling.
Bears, though? Oof. Seventy percent of revenue is still transaction-based, so any bear market and volumes crater—remember 2022 when revenue dropped 35% overnight. RSI is 72, stock’s a hundred percent above its 200-day moving average, classic overbought territory. Schwab and Fidelity are eating lunch with better tools and no payment-for-order-flow drama. SEC fines and regulatory heat never fully go away. If interest rates tank and volatility dries up, monthly active users stall hard. Bear DCF lands around fifty bucks. I’m riding the bull wave in a bull market, but I’ll be adding on any 20% pullback to eighty. Recessions turn HOOD into a pumpkin.
Last but not least, UNH—the healthcare behemoth that’s down 20% YTD to $310 after the cyberattack mess and Medicare headwinds. Still a dividend king with a 3% yield and four hundred billion in annual revenue. Optum is the growth engine—projected to two hundred billion by 2028 with AI squeezing costs and margins climbing past 8%. Medicare Advantage enrollment up double digits every year, EPS compounding 12% like clockwork. Post-dip, it’s trading 13x forward earnings versus an 18x historical average. Bull DCF says five hundred easy by 2028 as healthcare eats 20% of GDP. Ten billion annual buybacks and a track record of beating the S&P in ten of the last twelve bear markets. Management says full recovery in three to five years.
Bear case is regulatory Armageddon. DOJ is probing Optum acquisitions, Medicare could slice premiums 5%, medical loss ratios are stuck above 85% after the Change Healthcare breach cost them two billion and counting. Claims inflation is real, pricing power is slipping. Bear DCF lands at two hundred flat—35% downside from here. Policy risk under any administration is the wildcard. Still, I’m calling this a screaming value play. Bulls win the long game unless the regulators go full scorched earth.
Wrapping it: HIMS and HOOD are your growth moonshots—10%+ CAGR if stars align. UNH is the defensive cash cow that prints in any weather. Spread your bets, watch Q4 earnings for the next leg, and always do your own homework because Wall Street changes its mind faster than a diamond-hand paper-hands. What’s your play, degenerates? 🚀🩳

Bull & Bear cases Long-Term for HIMS, HOOD, and UNH ?

I'm short HIMS 38 puts exp today. The company is growing. But I just like to sell premium. What to do Thetagang?

Fomod into UUUU you’re not alone still holding $HIMS and $MP but kinda bought at the top. These bags are starting to hurt physically 😭

Voo, GLD,HIMS,DZP, NBIS, BMNR, MSFT

I bought the HIMS dip im ready for it to go flaccid again next week (please go up).

If NVDA takes HIMS and stays above $190 then ber will be in the stratosphere on Bezo’s Penis Rocket 9000

Buy shares set trailing stop.
I’m up 5% on some stuff from open with high beta like HIMS, SOFI, ACHR

I would love to buy myself some more NVO, NU, MAIN and HIMS (not really a value stock), but I don't have any cash left at the moment.
Salary arrives in 2 weeks so will get some then if the prices are still down.

You are probably not wrong. Just not right enough. If we're talking pure alpha in the metabolic disease game, let's zoom east to Hong Kong where the real fireworks are popping off. I'm eyeing Innogen-B (02591.HK) and PegBio (02565.HK) as straight-up superior moonshots right now, all laser-focused on the GLP-1 revolution that's exploding in Asia's massive diabetes and obesity market. These aren't diluted plays like UNH's insurance sprawl or HOOD's trading volatility; they're razor-sharp biotechs riding China's 1.4 billion-person wave, with approvals incoming and valuations that make US counterparts look like overpriced lattes. Let me break down why swapping some of that bag for these HK gems could 5x your portfolio by 2028—pure fire, no fluff.
First off, the macro setup in Hong Kong biotech is straight dominance mode. While the US Nasdaq biotech index is grinding up a measly 20% this year, Hong Kong's Hang Seng Biotech Index has ripped 80%+, outrunning even AI hype. Why? Beijing's pumping state cash into "Made in China 2025" for pharma independence, with 14 fresh listings already raising over HK$18 billion in 2025—quadrupling last year's haul—and 36 more queued up. Valuations? HK biotechs trade at 8-10x forward sales on average, versus 18x+ for US peers, giving you dirt-cheap entry into 30%+ CAGR growth as Asia's diabetes epidemic (hello, 140 million cases and counting) meets ultra-long-acting GLP-1s that crush Ozempic's dosing hassle. No DOJ probes or Medicare cuts here—just streamlined NMPA nods and export pipelines to Southeast Asia. HIMS is cute with its telehealth subs, but it's a US middleman facing Amazon's boot; these HK plays own the IP and manufacturing in the world's fastest-scaling market.
Take Innogen-B: This beast just exploded 296% on debut in August, opening at HK$72 after pricing at HK$18.68, and it's still humming around HK$50-60 with HK$683 million fresh in the tank from an IPO oversubscribed 5,365 times—HK$370 billion in bids from 260k investors, second-hottest in Hong Kong this year. Their crown jewel, Efsubaglutide Alfa (branded Diabegone), is Asia's first homegrown humanized long-acting GLP-1 agonist, already greenlit for type 2 diabetes in China and barreling through late-stage trials for obesity and MASH (that fatty liver goldmine worth $30 billion globally). Early data? 7% weight drop in four weeks, with monthly dosing that laps weekly shots—perfect for compliance in a market where 80% of patients ghost treatments. They're deploying IPO cash for Phase III global pushes, commercial ramps, and CNS add-ons, turning red ink (losses narrowed to HK$175 million last year) into black by mid-2026. Compared to HIMS' 50x P/E bloat and GLP-1 supply glut risks, Innogen's at <5x sales with zero revenue yet—pure asymmetry. Bears whine about Eli Lilly/Novo competition, but Innogen's local pricing edge (half the cost) and China-first moat mean they snag 10-15% market share easy, printing HK$10 billion revenue by 2030. UNH? It's a sleepy dividend cow at 13x earnings, dodging cyber headaches but capped at 8-10% growth; Innogen's your uncapped rocket to HK$300/share.
Then PegBio seals the deal as the stealth assassin. Listed earlier this year at HK$15.60, raising HK$301 million for a HK$6 billion val, it dipped to HK$10 on open but clawed back to HK$15+ on pipeline heat—up 7% monthly despite broader volatility. Their lead, PB-119, is another long-acting GLP-1 banger for diabetes and obesity, with NMPA acceptance last year and marketing greenlight eyed for Q1 2026. Preclinicals on PB-2301 (GLP-1/GIP dual) and PB-2309 (triple agonist) target NASH and rare endocrines, diversifying beyond HIMS' one-trick pony. R&D burn was HK$280 million in 2022, tapering to HK$76 million YTD as trials wrap, with cash at HK$27 million pre-IPO now beefed for launch and expansions. Losses ticked up slightly to HK$283 million last year on zero revenue, but that's biotech math—post-approval, ARPU from chronic scripts hits HK$500/year per patient in a 500 million obese Asian pool. Versus HOOD's cyclical 70% transaction reliance (hello, 35% revenue crater in '22), PegBio's recurring revenue moat is ironclad, with PEGylation tech for custom peptides adding service upside. Analysts are mum on ratings yet, but the sector tailwind screams Buy; at 4x projected sales, it's a steal next to UNH's regulatory quicksand (DOJ antitrust, 85% loss ratios). PegBio could 4x to HK$60 by 2027 if PB-119 captures 5% China share, while HOOD prays for bull markets.
Bottom line, apes: HIMS/HOOD/UNH are fine for balanced bags, but Innogen and PegBio are the asymmetric edges—cheaper entries, explosive China growth (20% GDP healthcare slice by 2030), and GLP-1 purity without US baggage. HK's policy rocket fuel means 50-100% pops on approvals alone, while US names grind through comps and comps. I'm allocating 20% here; dips under HK$45 for Innogen and HK$12 for PegBio are no-brainers. DYOR, markets flip fast, but this is where the smart money's flowing east. Who's jumping in? 🚀🇭🇰 #HKBiotech #GLP1Bets

I've recently started using Moomoo's AI for stock analysis and stock picking. I asked it to identify 10 potential 5-bagger stocks, and here’s the list it generated:
NVDA, AMD, SYM, SERV, NIO, UPST, HIMS, XPEV, VRTX, MRVL
Curious to hear—have any of you used Moomoo AI for investing? What’s been your experience?

Yo apes, dropping my two cents on the long-term bull/bear showdown for HIMS, HOOD, and UNH because someone asked for the real tea, not the CNBC fluff. This is 3-5 year horizon stuff, not day-trade noise, so buckle up. Everything here is fresh off Nov 2025 data—earnings, filings, analyst takes, short interest, the works. No copypasta, all reworded in my own voice. Let’s ride.
Starting with HIMS, the telehealth rocket that’s up triple digits this year and chilling around forty-five bucks a share. Forward earnings multiple is chunky at 50x, but the growth is stupid: 80%+ revenue pops projected straight through 2027, mostly riding the GLP-1 weight-loss wave plus mental health and women’s health add-ons. They’ve got 1.5 million subscribers now, average revenue per user climbing 20% year-over-year, and EBITDA margins just cracked 15%. Cash flow per share could hit five bucks by 2028 if they keep compounding. Hedge funds are stacking in—38 big players now versus 31 last quarter. Zacks slapped a Strong Buy on it. Bull case says they grab 5% of a hundred-billion-dollar telehealth pie and the stock prints two hundred or higher by decade’s end. The Novo Nordisk breakup? Shorts calling it a disaster, but bulls say it’s a nothing-burger—HIMS just pivots to their own compounded versions and keeps the party going.
Flip the script to the bear side and things get spicy. Short interest still north of 15%, gross margins are juicy at 80% but operating costs are ballooning. GLP-1 supply is gonna flood the market by 2027 and crush pricing power; right now 40% of revenue is one category. Amazon Pharmacy and Teladoc are lurking with deeper pockets and real infrastructure. DCF on the dark side spits out twenty bucks a share if growth throttles to 20%. One guy on here already dumped his entire bag calling the moat “non-existent.” DOJ is sniffing around compounding rules, and recessions make people skip the $99/month subscription real quick. Net-net, I’m tilting bullish if you buy dips under forty, but if the weight-loss hype dies, bears feast.
Next up, HOOD—the meme broker that turned legit and sits at $130 after a 150% YTD rip. Funded accounts over 25 million and growing 30% year-over-year, average revenue per user north of $150 thanks to crypto trading (20% of revenue), margin loans, and Robinhood Gold subs hitting a million users. They’re sitting on six billion cash, zero debt, and just bought a crypto wallet to keep expanding. Crypto ETFs are soaking up fifty billion in inflows, retail is back in force, and 24/7 trading plus new ETF launches scream “everything app” for millennials and Gen Z. Technicals show a consolidation triangle ready to break; Mizuho’s old fourteen-dollar target got obliterated months ago. Bull case says three hundred to four hundred by 2030 if the risk-on party keeps rolling.
Bears, though? Oof. Seventy percent of revenue is still transaction-based, so any bear market and volumes crater—remember 2022 when revenue dropped 35% overnight. RSI is 72, stock’s a hundred percent above its 200-day moving average, classic overbought territory. Schwab and Fidelity are eating lunch with better tools and no payment-for-order-flow drama. SEC fines and regulatory heat never fully go away. If interest rates tank and volatility dries up, monthly active users stall hard. Bear DCF lands around fifty bucks. I’m riding the bull wave in a bull market, but I’ll be adding on any 20% pullback to eighty. Recessions turn HOOD into a pumpkin.
Last but not least, UNH—the healthcare behemoth that’s down 20% YTD to $310 after the cyberattack mess and Medicare headwinds. Still a dividend king with a 3% yield and four hundred billion in annual revenue. Optum is the growth engine—projected to two hundred billion by 2028 with AI squeezing costs and margins climbing past 8%. Medicare Advantage enrollment up double digits every year, EPS compounding 12% like clockwork. Post-dip, it’s trading 13x forward earnings versus an 18x historical average. Bull DCF says five hundred easy by 2028 as healthcare eats 20% of GDP. Ten billion annual buybacks and a track record of beating the S&P in ten of the last twelve bear markets. Management says full recovery in three to five years.
Bear case is regulatory Armageddon. DOJ is probing Optum acquisitions, Medicare could slice premiums 5%, medical loss ratios are stuck above 85% after the Change Healthcare breach cost them two billion and counting. Claims inflation is real, pricing power is slipping. Bear DCF lands at two hundred flat—35% downside from here. Policy risk under any administration is the wildcard. Still, I’m calling this a screaming value play. Bulls win the long game unless the regulators go full scorched earth.
Wrapping it: HIMS and HOOD are your growth moonshots—10%+ CAGR if stars align. UNH is the defensive cash cow that prints in any weather. Spread your bets, watch Q4 earnings for the next leg, and always do your own homework because Wall Street changes its mind faster than a diamond-hand paper-hands. What’s your play, degenerates? 🚀🩳

Bull & Bear cases Long-Term for HIMS, HOOD, and UNH ?